m.coelho

TL2 · Łódź

Contributes reviews on supplier material. Based in Łódź.

Joined 18 August 2025 · last posted 8d

85 posts, newest first. Showing up to 150.

Priming a pen and whether the primed volume is wasted Replied, post #14 · Devices › Pens & autoinjectors · 20 Jul 2026 · 2 likes Nothing here is medical advice, and pen technique is the single easiest thing to have demonstrated in person rather than learned from a description.
Reading order for a first week here, and what to skip until later — what changed since Replied, post #62 · Start Here › Welcome · 20 Jul 2026 · 1 like Answering the Reading order question as asked, then the question I think is meant. As asked: yes, with the qualification below. As meant: it depends on how the first…
Second pass at: Sleep apnoea improving and the equipment implications Replied, post #81 · Wellbeing › Sleep · 10 Jul 2026 · 15 likes Energy availability affects sleep in both directions, and a large deficit can produce either fragmentation or unusual sleepiness. Someone should write this up properly,…
Submitting a sample: the process end to end Replied, post #66 · Sourcing › Independent verification · 8 Jul 2026 · 27 likes Following, with nothing to contribute beyond having asked the same thing elsewhere.
BPC-157: what the rodent literature actually shows, and what it does not — does this… Replied, post #3 · Compounds › Repair & healing peptides · 7 Jul 2026 · 1 like Stability of BPC-157 in solution: what has been measured in published work covers specific formulations under specific conditions. Extrapolating to a reconstituted…
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #34 · Practice › Dosing & titration · 3 Jul 2026 · 31 likes Appreciated. The plain phrasing does more work here than a longer post would.
[2026 update] Detection wavelength and why 214 nm and 280 nm disagree Replied, post #8 · Analytics › HPLC & UHPLC · 2 Jul 2026 · 0 likes A relative retention time against a known peak travels much better than an absolute one, and almost nobody reports it. I have written this out at length because the…
Why we ask for units every single time, with three examples of what goes wrong Replied, post #89 · Start Here › How to Ask · 2 Jul 2026 · 1 like Building on post #88 rather than restating it. A photograph of a vial is rarely useful and a photograph of a document usually is. Redact the identifiers before you post…
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #52 · Evidence › Journal club · 28 Jun 2026 · 22 likes Reading order that works for these sessions: registry entry, methods, baseline table, primary result, then abstract last. Reading the abstract first anchors everything…
Athletes in weight-category sports: a different risk calculus Replied, post #3 · Clinical › Special populations · 25 Jun 2026 · 16 likes Extrapolating a point estimate to somebody well outside the enrolled range should be described as an extrapolation every time it is done.
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #25 · Analytics › Home & field testing · 24 Jun 2026 · 0 likes This settles it for me, at least until somebody posts a reason it should not.
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #12 · Compounds › Retatrutide · 22 Jun 2026 · 8 likes What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose response in diverse populations, whether the heart-rate…
Racemisation and why it is invisible to a mass measurement Replied, post #18 · Analytics › Impurities & related substances · 9 Jun 2026 · 0 likes An impurity profile that changes between lots is more informative than the total. A stable profile suggests a controlled process; a shifting one suggests something is…
A certificate whose chromatogram axes do not match its stated method — one year on Replied, post #87 · Sourcing › Red flags · 6 Jun 2026 · 1 like The guidelines draw that line for a practical reason as much as a fair one: reports accumulate into something useful and allegations do not.
A checklist for reading a certificate in under two minutes Replied, post #33 · Analytics › COA interpretation · 3 Jun 2026 · 0 likes Taking post #30 at face value and following it one step further. Reading old certificates: if a certificate is dated years ago, the lot it describes might be old. That…
Bariatric surgery history: altered anatomy, altered expectations Replied, post #27 · Clinical › Special populations · 27 May 2026 · 10 likes Marking my place. If it changes for me I will come back and say so.
Micro-titration: a disputed topic, argued properly Replied, post #79 · Practice › Dosing & titration · 24 May 2026 · 6 likes An update on my earlier micro-titration post: the pattern held for another six weeks and then stopped, which I did not predict and cannot explain.
Tracking a shortage from primary sources rather than rumour Replied, post #10 · Access › Shortages · 15 May 2026 · 22 likes The most useful contribution is a link to the current official notice rather than an account of one pharmacy. The step people skip is the one I have spelled out.
Subgroup analyses: pre-specified versus discovered — a second dataset Replied, post #69 · Evidence › Trials · 2 May 2026 · 10 likes Post #68 is right about the mechanism and I think understates the practical bit. Absolute numbers, not just relative: a 30% relative reduction tells you the ratio but…
Completing a dose with a second syringe, and the dead-volume arithmetic Replied, post #34 · Practice › Administration · 30 Apr 2026 · 0 likes The thing about completing a dose that took me longest to accept is that a plausible mechanism is not evidence of an effect. It is a reason to look, not a result.
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ — does this still hold? Replied, post #8 · Sourcing › Independent verification · 29 Apr 2026 · 10 likes Post #4 and I disagree about the size of the effect, not about the direction. Service differences on vendor pages: Janoshik and Medutest results are measurements on…
Coming back to: Measurement error in a self-reported exposure Replied, post #9 · Evidence › Study critique · 22 Apr 2026 · 3 likes Where I part company with post #7, and it is a narrow parting. Distinguishing three things in the Measurement error discussion that keep getting used interchangeably:…
Pregnancy and pregnancy planning: contraindication and washout Replied, post #114 · Clinical › Special populations · 17 Apr 2026 · 28 likes I read post #110 twice before replying, because I had assumed the opposite. Body weight at the extremes of the studied range affects exposure and the trials rarely…
CJC-1295 with and without DAC: what the modification does Replied, post #34 · Compounds › Secretagogues & GH axis · 15 Apr 2026 · 2 likes Post #32 answers the question as asked. The question underneath it is different. The confident answers on CJC-1295 and the well-sourced answers are not the same…
Coming back to: Swirling versus inverting versus leaving it alone Replied, post #8 · Practice › Reconstitution · 14 Apr 2026 · 15 likes The arithmetic in post #5 is right; the assumption feeding it is the part to check. Preservative effectiveness is tested against a defined microbial challenge under…
The 2.5 mg starting dose is not a therapeutic dose — why that matters Replied, post #82 · Compounds › Tirzepatide · 14 Apr 2026 · 0 likes SURMOUNT-4 used a randomised withdrawal design: everyone titrated, then those on maintenance were randomised to continue or placebo. Continuation maintained effect;…
Why the timeline is on the right and not the left — what changed since Replied, post #18 · Meta › Site feedback · 10 Apr 2026 · 29 likes I had written a reply contradicting post #16 and deleted it. Here is what survived. The thing about timeline that took me longest to accept is that a plausible…
Revisiting: Drawing up with one needle and injecting with another Replied, post #67 · Practice › Administration · 7 Apr 2026 · 11 likes Post #65 describes the usual case. This is about the unusual one. If you have to inject at a different time of day than usual, that is a much smaller perturbation than…
The "under review" status pill and when a moderator applies it Replied, post #36 · Evidence › Preprints · 25 Mar 2026 · 19 likes Screening on a preprint server is minimal and is not review. It filters obvious problems and nothing more, which is what it is designed to do. Correct me on the…
Blinding yourself: practical methods and their limits Replied, post #13 · Research Methods › N-of-1 designs · 24 Mar 2026 · 0 likes Two questions I would want answered before drawing anything from the blinding yourself data above: how were the cases selected, and what happened to the ones that…
Preprint servers and what screening they do Replied, post #85 · Evidence › Preprints · 11 Mar 2026 · 16 likes Post #81 describes the usual case. This is about the unusual one. Where a preprint contradicts a published trial, the prior should favour the trial. Where it extends…
A supplier who responds to a discrepancy with silence — what changed since Replied, post #15 · Sourcing › Red flags · 11 Mar 2026 · 0 likes Right, and stated more narrowly than I would have dared to state it.
Amylin receptor signalling and satiety — what changed since Replied, post #24 · Pharmacology › Receptor biology · 1 Feb 2026 · 0 likes Endogenous versus pharmacological receptor engagement differ in magnitude and in duration by orders of magnitude. Arguments from "it is a natural hormone" do not…
Designing a personal experiment that could change your mind — one year on Replied, post #5 · Research Methods › N-of-1 designs · 25 Jan 2026 · 0 likes The interesting personal experiments are the ones where the answer was no. They are also the ones least likely to be written up. I would not lead a decision with this,…
MHRA statements, read directly Replied, post #71 · Regional › UK & Ireland · 19 Jan 2026 · 16 likes Post #68 answers the question as asked. The question underneath it is different. What would change my mind on MHRA statements is a second dataset collected by someone…
Constipation management, with a dietitian's contribution Replied, post #19 · Practice › Side effects · 14 Jan 2026 · 1 like Post #17 put the caveat in the right place and I want to underline it. The relationship between symptom burden and outcome is not what people assume. Feeling worse is…
Personal import allowances, compared — a second dataset Replied, post #51 · Access › International · 13 Jan 2026 · 2 likes Adding what did not work for me on Personal import allowances, since the failures never get written up and they are half the useful information.
Coming back to: Washout: how long is long enough, and for what purpose Replied, post #11 · Pharmacology › Pharmacokinetics · 8 Jan 2026 · 14 likes On post #9 — agreed on the reasoning, with one qualification. Washout after stopping takes roughly the same four to five half-lives as reaching steady state. A month…
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long… Replied, post #73 · Compounds › Tirzepatide · 10 Dec 2025 · 0 likes Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how much is simply achieving higher receptor engagement? The honest answer is that…
What a purity-only report leaves out Replied, post #103 · Sourcing › Independent verification · 26 Nov 2025 · 7 likes Clear enough that I do not think I have a follow-up, which is unusual.
What a reversed-phase purity number actually is — the long version Replied, post #3 · marked as the solution · Analytics › HPLC & UHPLC · 23 Nov 2025 · 9 likes Gradient slope is the single biggest driver of apparent purity differences. A shallower gradient over a longer run resolves more impurities and gives a higher purity…
Warfarin and altered intake: the monitoring argument — the long version Replied, post #51 · Practice › Interactions · 16 Nov 2025 · 0 likes Sulfonylureas and meglitinides: these agents stimulate insulin release and carry hypoglycemia risk. Combining them with semaglutide or tirzepatide requires dose…
Pharmaceutical compounding rules, summarised from primary sources — a second dataset Replied, post #12 · Sourcing › Regulatory · 2 Nov 2025 · 1 like Post #9 is the version of this I will quote in future. One addition. The documentation on Pharmaceutical compounding rules is better than this thread and I say that as…
Tirzepatide molecular mass and the charge states you would expect on ESI — does this… Replied, post #5 · Compounds › Tirzepatide · 30 Oct 2025 · 0 likes Titration schedules for tirzepatide have more dose steps than semaglutide partly because the compound is more potent and partly because the clinical programme used a…
EMA product information as a primary source Replied, post #7 · Regional › European Union · 27 Oct 2025 · 14 likes Reading rather than answering, but this is the post I would point somebody at.
Coming back to: Over-dilution: when your dose falls below one readable graduation Replied, post #58 · Practice › Reconstitution · 21 Sep 2025 · 2 likes On Over-dilution: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here…
Revisiting: Reading a denial letter as a specification for your appeal Replied, post #128 · Access › Insurance & coverage · 21 Sep 2025 · 3 likes Appreciated. The plain phrasing does more work here than a longer post would.
Semaglutide versus liraglutide head to head: reading STEP 8 carefully Replied, post #57 · Compounds › Semaglutide · 12 Sep 2025 · 30 likes On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species.…
Hypertension improvement and when medication needs revisiting Replied, post #55 · Clinical › Comorbidities · 12 Sep 2025 · 0 likes A condition that affects nutrition or absorption changes the calculus around a treatment that reduces intake, and that interaction is mostly unstudied.
Tirzepatide molecular mass and the charge states you would expect on ESI Replied, post #38 · Compounds › Tirzepatide · 30 Aug 2025 · 1 like Content versus purity applies here as everywhere: a lyophilised vial can be highly pure and contain less peptide than the label states, because the balance of the mass…
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how… Replied, post #99 · Compounds › Tirzepatide · 3 Aug 2025 · 15 likes The arithmetic in post #96 is right; the assumption feeding it is the part to check. A request rather than an answer: could whoever has the primary source for GIP…
A pen that felt like it delivered nothing: diagnosing it afterwards Replied, post #11 · Devices › Pens & autoinjectors · 20 Jul 2025 · 4 likes Post #7 and I disagree about the size of the effect, not about the direction. Storage instructions for a pen typically differ before and after first use, and the in-use…
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly Replied, post #134 · Compounds › Tirzepatide · 12 Jul 2025 · 4 likes Two questions I would want answered before drawing anything from the tirzepatide in type 2 diabetes data above: how were the cases selected, and what happened to the…
Sequence verification for an obscure compound: how it is done Replied, post #89 · Compounds › Other compounds · 11 Jul 2025 · 12 likes A compound with no established assay is a compound where a certificate can say almost anything. That is not an accusation about anyone; it is a statement about what a…
Regional warehouse stock versus direct despatch Replied, post #3 · Sourcing › Logistics · 11 Jun 2025 · 30 likes Adding the measurement that the opening post says would settle it. Where I would push back on the regional warehouse stock versus direct consensus is the confidence,…
The CagriSema phase 2 paper and what a fixed combination buys Replied, post #46 · Compounds › Cagrilintide & amylin analogues · 24 May 2025 · 15 likes Distinguishing three things in the cagrisema phase 2 paper discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the…
Second pass at: Pen dose counters: what a click does and does not guarantee Replied, post #46 · Devices › Pens & autoinjectors · 22 May 2025 · 10 likes A pen that has been dropped may not be visibly damaged and may not deliver accurately afterwards. Manufacturers say to replace rather than to test, and there is no test…
Pregnancy as an absolute contraindication Replied, post #71 · Safety › Contraindications · 19 May 2025 · 10 likes Post #70 is the version of this I will quote in future. One addition. Severe hepatic impairment: less is known than for kidney disease. Extreme caution or…
Journal club: SURMOUNT-4 and continuation versus withdrawal — a second dataset Replied, post #34 · Evidence › Journal club · 18 May 2025 · 1 like That is a cleaner way of putting what I was circling around.
A report I filed that turned out to be wrong, and the correction Replied, post #51 · Sourcing › Vendor reports · 13 May 2025 · 0 likes The cost of a submission is worth stating. It is the main reason people do not do this and knowing the figure helps somebody else decide.
Revisiting: German, French and Dutch differences, compared Replied, post #20 · Regional › European Union · 10 May 2025 · 10 likes My understanding of German is a few years old and may have been superseded. If it has been, I would genuinely like to know rather than keep repeating it.
Holding a dose indefinitely: is there a documented downside? Replied, post #19 · Practice › Dosing & titration · 27 Apr 2025 · 33 likes I read post #17 twice before replying, because I had assumed the opposite. Writing down the date, the dose and the site each week takes fifteen seconds and is the…
Relative retention time as a better inter-laboratory comparator Started this topic · Analytics › Method validation · 9 Apr 2025 · 18 likes On the subject in the title: Relative retention time as a better inter-laboratory comparator Working notes rather than a conclusion. What changes if the standard…
Follow-up: Open-label extensions: what survives and what does not Replied, post #20 · Evidence › Trials · 27 Mar 2025 · 16 likes What I would check first on Open-label extensions is whether the thing being measured moved or whether the way of measuring it moved. Those look identical in a graph.
Maintainer handover: how it works Replied, post #71 · Meta › Wiki maintenance · 18 Mar 2025 · 28 likes No disagreement from me. Posting only so the question does not look ignored.
Amylin analogue mechanism: satiety signalling separate from GLP-1 Replied, post #76 · Compounds › Cagrilintide & amylin analogues · 6 Mar 2025 · 24 likes Amylin analogue mechanism would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.
Consistent declarations and why they matter more than clever ones Replied, post #47 · Sourcing › Logistics · 17 Feb 2025 · 23 likes Worth separating two things that post #46 runs together. If you are new and reading this thread for the answer to consistent declarations: the answer is conditional,…
A 5 mg vial and a 0.25 mg dose: the arithmetic in full — the long version Replied, post #34 · Practice › Reconstitution · 16 Feb 2025 · 4 likes Two people can reconstitute the same vial to different concentrations and both be right. The dose is the same; only the volume drawn differs. This confuses more…
Random versus fixed effects: choosing rather than defaulting — a second dataset Replied, post #83 · Evidence › Meta-analyses · 9 Feb 2025 · 9 likes This follows post #82 rather than contradicting it. I think the Random versus fixed effects question is answerable and has not been answered, which is a more optimistic…
Domestic fridge temperature mapping: a cheap experiment — what changed since Replied, post #49 · Devices › Cold chain · 9 Feb 2025 · 20 likes Temperature excursions: brief excursions above 8 °C are tolerable for most compounds. Hours to a day at room temperature is usually acceptable. Days to weeks at room…
Ipamorelin selectivity claims and where they came from Replied, post #11 · Compounds › Secretagogues & GH axis · 5 Feb 2025 · 19 likes Post #9 answers the question as asked. The question underneath it is different. Two people in this thread mean different things by ipamorelin selectivity claims and are…
Second pass at: A pen that felt like it delivered nothing: diagnosing it afterwards Replied, post #9 · Devices › Pens & autoinjectors · 14 Jan 2025 · 15 likes Disposal of a used pen is a sharps question even where the needle is retracted, and local rules vary more than people expect. A partial answer, offered because a…
Reading a supplementary appendix and finding the interesting part Replied, post #59 · Evidence › Trials · 4 Jan 2025 · 22 likes Post #56 is right about the mechanism and I think understates the practical bit. Discontinuation handling is the methodological detail that most changes a result and…
Oral semaglutide bioavailability and its variability between people — a second dataset Replied, post #6 · Compounds › Oral incretins · 25 Dec 2024 · 3 likes PIONEER 6 is the cardiovascular outcome trial for oral semaglutide and it enrolled a diabetes population at high cardiovascular risk. Quoting it outside that population…
Building a sensible monitoring schedule with your prescriber Replied, post #90 · Clinical › Bloodwork · 22 Dec 2024 · 9 likes Adding a note of thanks rather than an opinion. I did not know most of that.
Coming back to: Research-use-only labelling: what it means and what it does not Replied, post #31 · Sourcing › Regulatory · 17 Nov 2024 · 0 likes Appreciated. The plain phrasing does more work here than a longer post would.
Reading a preclinical wound-healing model and its relevance to a human tendon Replied, post #49 · Compounds › Repair & healing peptides · 13 Nov 2024 · 0 likes Picking up post #46: that is the part I would want checked first. Anecdote is the whole of the human evidence base here, and this community's convention is to say so…
Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Replied, post #90 · Compounds › Other compounds · 3 Nov 2024 · 0 likes Reading this Melanocortin agonists thread as someone who came in with a fixed view: the third and seventh replies moved me and the confident ones did not.
Follow-up: A site rotation scheme that is easy enough to actually follow Replied, post #19 · Practice › Administration · 10 Sep 2024 · 27 likes Understood, and I withdraw the assumption I opened with.
Second pass at: Reimbursement variation across member states Replied, post #6 · Regional › European Union · 4 Sep 2024 · 2 likes EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member…
Pen wastage and its effect on real cost Replied, post #20 · Access › Pricing · 30 Aug 2024 · 2 likes A pen and a vial are not the same product. Dead volume, wastage and the number of doses actually obtainable all differ.
Guidelines revision: what changed and why Replied, post #29 · Meta › Announcements · 25 Jul 2024 · 0 likes The edit is clearer. For anyone arriving now, read the edited version — the confusion in the replies above is about wording that no longer exists. I looked this up…
How this community labels and discusses unrefereed work Replied, post #110 · Evidence › Preprints · 24 Jul 2024 · 0 likes Post #109 is the version of this I will quote in future. One addition. The most useful thing anyone has posted about community labels in this category was a table of…
Blind submission and why it changes minds Replied, post #16 · Sourcing › Independent verification · 16 Jul 2024 · 3 likes Janoshik Analytical: chromatographic purity and mass-spectrometric identity on submitted samples. Reports are issued with the analytical method stated and a…
Where the four-week escalation interval comes from, and what it is not Replied, post #18 · Practice › Dosing & titration · 11 Jun 2024 · 0 likes Worth separating four-week escalation interval as a question about the compound from four-week escalation interval as a question about the documentation. They get…